Serum interleukin-18 concentrations in patients with inflammatory bowel disease

被引：34

作者：

Furuya, D

Yagihashi, A

Komatsu, M

Masashi, N

Tsuji, N

Kobayashi, D

Watanabe, N

机构：

[1] Sapporo Med Univ, Sch Med, Dept Clin Lab Med, Chuo Ku, Sapporo, Hokkaido 0608543, Japan

[2] Sapporo Med Univ, Sch Med, Div Lab Diag, Sapporo, Hokkaido, Japan

来源：

JOURNAL OF IMMUNOTHERAPY | 2002年 / 25卷

关键词：

interleukin-18; enzyme-linked immunosorbent assay; inflammatory bowel disease; Crohn disease; ulcerative colitis;

D O I：

10.1097/00002371-200203001-00010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Elevated expression of interleukin (IL)-18 mRNA and protein in intestinal mucosa, attributable to activated monocytes and macrophages in that site, has been reported in patients with inflammatory bowel disease (IBD). However, changes in serum IL-18 concentrations in patients with IBD have not been reported. We measured bioactive IL-18 in serum from patients with IBD, using an enzyme-linked immunosorbent assay (ELISA). Mean serum IL-18 concentrations in 5 patients with Crohn disease (CD) were 400 pg/mL, approximately 1.7 times higher than concentrations in 21 control subjects (p < 0.01). However, serum IL-18 was not increased in patients with ulcerative colitis (UC). These results suggest that like other T-helper type 1 (Th1) cytokines IL-18 may play a key pathogenetic role in Th1-mediated disorders, such as CD. Regulation and expression of IL-18 appears to differ between CD and UC, and serum IL-18 may be a useful clinical marker for CD.

引用

页码：S65 / S67

页数：3

共 19 条

[1] Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells [J].